Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study

被引：0
|
作者：
Coveler, Andrew L.
Reilley, Matthew
Zalupski, Mark
Macarulla, Teresa
Fountzilas, Christos
Castanon Alvarez, Eduardo
Nagrial, Adnan
Volodymyrivna Uboha, Nataliya
Frentzas, Sophia
Overman, Michael J.
Noonan, Anne M.
Messersmith, Wells A.
Pavlakis, Nick
Mettu, Niharika B.
Smith, Paul
Murtomaki, Elina
Bragulat, Veronique
Cooper, Zachary A.
Kumar, Rakesh
Spigel, David
机构：
[1] Fred Hutchinson Canc Ctr, Seattle, WA USA
[2] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[4] Hosp Univ Vall DHebron, Barcelona, Spain
[5] Roswell Pk Canc Inst, Buffalo, NY USA
[6] Clin Univ Navarra, Madrid, Spain
[7] Blacktown Hosp, Sydney, NSW, Australia
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Monash Hlth Monash Med Ctr, Clayton, Vic, Australia
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[12] Univ Colorado, Denver, CO USA
[13] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia
[14] Duke Univ, Med Ctr, Durham, NC USA
[15] AstraZeneca, Cambridge, England
[16] AstraZeneca, Gaithersburg, MD USA
[17] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Coveler, Andrew L.
    Reilley, Matthew J.
    Zalupski, Mark
    Macarulla, Teresa
    Fountzilas, Christos
    Ponz-Sarvise, Mariano
    Nagrial, Adnan
    Uboha, Nataliya V.
    Frentzas, Sophia
    Overman, Michael
    Noonan, Anne
    Messersmith, Wells A.
    Pavlakis, Nick
    Mettu, Niharika B.
    Bisha, Ina
    Wang, Ying
    Smith, Paul
    Murtomaki, Elina
    Bielska, Agata A.
    Bragulat, Veronique
    Cooper, Zachary A.
    Kumar, Rakesh
    Spigel, David R.
    CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4609 - 4617
  • [2] A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
    O'Reilly, Eileen Mary
    Oh, Do-Youn
    Dhani, Neesha
    Renouf, Daniel John
    Lee, Myung Ah
    Sun, Weijing
    Fisher, George A.
    Hezel, Aram F.
    Chang, Shao-Chun
    Vlahovic, Gordana
    Takahashi, Osamu
    Yang, Yin
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study
    Prenen, Hans
    Borbath, Ivan
    Paula Geboes, Karen
    Alexandre Cassier, Philippe
    Lambert, Aurelien
    Mitry, Emmanuel
    Macarulla, Teresa
    Taieb, Julien
    Blanc, Jean-Frederic
    Feliu Batlle, Jaime
    Rodriguez Garrote, Mercedes
    Pazo Cid, Roberto A.
    Valladares-Ayerbes, Manuel
    Nordbladh, Karin
    Enell Smith, Karin
    Ellmark, Peter
    Carlsson, Malin
    Pico de Coana, Yago
    Vijay Ambarkhane, Sumeet
    Van Laethem, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
    O'Reilly, Eileen M.
    Oh, Do-Youn
    Dhani, Neesha
    Renouf, Daniel J.
    Lee, Myung Ah
    Sun, Weijing
    Fisher, George
    Hezel, Aram
    Chang, Shao-Chun
    Vlahovic, Gordana
    Takahashi, Osamu
    Yang, Yin
    Fitts, David
    Philip, Philip Agop
    JAMA ONCOLOGY, 2019, 5 (10) : 1431 - 1438
  • [5] A phase 2, open-label, multicenter study of durvalumab (MEDI4736) tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.
    O'Reilly, Eileen Mary
    Oh, Do-Youn
    Lee, Myung Ah
    Dhani, Neesha
    Armstrong, Jon
    Belli, Riccardo
    Ferro, Salvatore
    Ben, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Walker, Evan Justin
    Fountzilas, Christos
    Borazanci, Erkut Hasan
    Shields, Anthony F.
    D'Olimpio, James Thomas
    Hecht, J. Randolph
    Tang, Shou-Ching
    Michelson, Glenn
    Liganor, Lorna
    Cho, Sangsook Ahn
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666
  • [7] AVELUMAB plus BINIMETINIB IN METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC): DOSE-ESCALATION RESULTS FROM THE PHASE 1B/2 JAVELIN PARP MEKI TRIAL
    Rodon, Jordi
    Tan, Daniel Weng
    Laguna, Ignacio Garrido
    Harb, Wael
    Beck, J. Thaddeus
    Bahary, Nathan
    Rottey, Sylvie
    Zhu, Zhou
    Deng, Shibing
    Kowalski, Karen
    O'Neill, Grainne
    Wei, Caimiao
    Pathan, Nuzhat
    Messersmith, Wells
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A371 - A371
  • [8] OPTIMIZE-1, AN OPEN-LABEL PHASE 1B/2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAZALIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    de Coana, Yago Pico
    Smith, Karin Enell
    Falt, Anette
    Flardh, Maria
    Ellmark, Peter
    Cassier, Philippe
    van Laethem, Jean-Luc
    Carlsson, Malin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A567 - A567
  • [9] Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Prenen, Hans
    Lambert, Aurelien
    Geboes, Karen
    Blanc, Jean-Frederic
    de Coana, Yago Pico
    Enell-Smith, Karin
    Schultz, Lena
    Nordbladh, Karin
    Ellmark, Peter
    Ambarkhane, Sumeet
    Carlsson, Malin
    Cassier, Philippe
    CANCER RESEARCH, 2022, 82 (22) : 10 - 11
  • [10] CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study
    Van Laethem, Jean-Luc
    Geboes, Karen P.
    Cassier, Philippe A.
    Borbath, Ivan
    Lambert, Aurelien
    Mitry, Emmanuel
    Prenen, Hans
    Blanc, Jean-Frederic
    Pilla, Lorenzo
    Garrote, Mercedes Rodriguez
    Cid, Roberto A. Pazo
    Gallego, Inmaculada
    Feliu, Jaime
    Nordbladh, Karin
    Ellmark, Peter
    Carlsson, Malin
    de Coana, Yago Pico
    Ambarkhane, Sumeet V.
    Macarulla, Teresa
    CANCER RESEARCH, 2024, 84 (02)
12345